Scrip is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


Carole Goldsmith

Set Alert for Articles By Carole Goldsmith

Latest From Carole Goldsmith

Considering Growth Options For Asian Biotechs: IPO Vs M&A

Going public via an IPO or being acquired are two ways that Asian biotech companies can grow their business, and some of the issues involved in both approaches come under discussion at a panel session at a recent conference in Singapore.

Asia Pacific Commercial

Nanjing BioPoint Shoots For 2018 Double POC Launch; Seeks $10m

A China-based IVD company, spun out of an Australian medical research institute, is seeking investors to support its plans for the 2018 launch its first two point-of-care tests for patients with infectious diseases including HIV and viral hepatitis.

In Vitro Diagnostics Financing

Local Expertise Key To Tackling China Market: AusBiotech Meeting

Speakers from the legal, corporate and contract research sectors discussed the fast-moving changes that are impacting the legal and regulatory aspects of doing business in China at the recent AusBiotech conference in Melbourne, providing a broad range of advice for Australian and other pharma and biotech companies wanting to enter the rapidly expanding Chinese life sciences market.

BioPharmaceutical China

Asia-Pacific Trade Talks Prompt Concerns, Optimism

The Public Health Association of Australia has expressed concerns over leaked TRIPS-plus intellectual property proposals from the planned Asian Regional Comprehensive Economic Partnership agreement, while Medicines Australia says the planned Trans Pacific Partnership has the potential to establish high regional standards for IP protection.

BioPharmaceutical Asia Pacific

CONFERENCE REPORT: Getting To Grips With China’s Medtech Market

With some research valuing China’s strongly growing medical devices market at already more than $16 billion, the fourth-largest in the world and the second in Asia behind Japan, serious consideration of the sector has become critical. Speakers at the recent AusBiotech conference in Melbourne provided valuable insight for medtech companies wanting to better understand or enter China’s medical devices market.

Medical Device China

Growing Globally And Tapping Expertise: Tales From Bio Korea

South Korea’s Boryung Pharm has now signed $1 billion worth of global agreements for its antihypertensive Kanarb, while U.S. regenerative medicine company Orgenesis, which is working to cure type 1 diabetes with technology that combines cellular and regenerative therapy, has signed collaborative deals with two Korean partners, a recent meeting in Seoul heard.

BioPharmaceutical Asia Pacific
See All